Results

Total Results: 1,292 records

Showing results for "how to do a case study".

441. Disposition of Comments Report for Intravascular Diagnostic Procedures and Imaging Techniques Versus Angiography Alone in Coronary Artery Stenting (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/coronary-artery-stenting_disposition-comments.pdf
     February 26, 2013 - We do not make clinical practice recommendations, and this review should not be mistaken for a Clinical … We do hope that the future CER reports will incorporate such decision- analytical frameworks to guide … I do feel more work and clarity is need before this document a=can be “used to inform policy and/or … or not to stent (KQ1) and how to place the stent once the decision to stent has been made (KQ2). … The evidence supporting OCT also continues to increase rapidly as clinicians better understand how the

442. Revised Protocol - Opioids 12 13 13[1] (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/chronic-pain-opioid-treatment_research-protocol.pdf
     December 19, 2013 - How do harms vary depending on: 1) the specific type or cause of pain (e.g., neuropathic, musculoskeletal … For all key questions, we will exclude uncontrolled observational studies, case series, and case reports … For Key Question IVa, we will exclude studies that do not evaluate the performance of a risk prediction … Technical Experts do not do analysis of any kind nor contribute to the writing of the report and have … not reviewed the report, except as given the opportunity to do so through the peer or public review

443. Disposition of Comments for Epoetin and Darbepoetin for Managing Anemia in Patients Undergoing Cancer Treatment (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/cancer-anemia-update_disposition-comments.pdf
     April 25, 2013 - Second, while erythropoietin and thrombopoietin share a 20 % homology, ESAs do not stimulate thromboppoiesis … the guidelines (in the name of research) of how to use ESAs safely. … Results continued Page 59, line 37: Here, and throughout the review, the authors do a thorough job … How does this argument strengthens support for a causal effect? … arm (84% versus 46%) who do not respond and remain at a hemoglobin level of 9 g/dL or lower for an

444. Grading_didactic_faculty_approved (ppt file)
     effectivehealthcare.ahrq.gov/sites/default/files/grading.ppt
     January 01, 2013 - : A comprehensive evaluation of the evidence A sense of how much confidence they can place in the … Reviewers do not need to make assumptions about the link between use of the intervention and proxy, surrogate … Apart from deciding how best to proceed, reviewers need to understand that this is a complex step requiring … and decide how to weight the domains when assigning the evidence grade. … Do not use Roman numerals or other symbols.

445. Cell-Free-Dna-Appendix-C-Prepub-Final (xls file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/cell-free-dna-appendix-c-prepub-final.xlsx
     January 01, 2025 - Glycans Mass spectrometry Plasma Frozen 371 55 14 (outlier results) 24 or 21 (numbers do not add up correctly … Unclear exactly how cancer cases were confirmed; MCST collection was prior to any treatment. … Yes Yes Low concerns Thresholds were established in previous studies; authors do present findings of … These appear to be public/governmental funding agencies which generally do not have conflicts of interest … Public grant organizations typically do not have conflicts of interest.

446. Cell-Free-Dna-Final-App-C (xls file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/cell-free-dna-final-app-c.xlsx
     January 01, 2025 - Glycans Mass spectrometry Plasma Frozen 371 55 14 (outlier results) 24 or 21 (numbers do not add up correctly … Unclear exactly how cancer cases were confirmed; MCST collection was prior to any treatment. … Yes Yes Low concerns Thresholds were established in previous studies; authors do present findings of … These appear to be public/governmental funding agencies which generally do not have conflicts of interest … Public grant organizations typically do not have conflicts of interest.

447. Carman-notes-151021 copy-Teresa (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/carman-presentation.pdf
     May 29, 2025 - really asked us to think, “How do we think about patient and   family engagement? … I have a mutual interest to do so. … How do I get the patient to fit into my research agenda? … S o I do want to say just a word  about how we do this in  evidence based  healthcare especially … how we do this in  research.

448. Disposition of Comments: Comparative Effectiveness Review 235_Pharmacologic and Nonpharmacologic Treatments for Posttraumatic Stress Disorder: An Update of the PTSD-Repository Evidence Base (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/ptsd-comments.pdf
     November 04, 2020 - I know it's rare for authors to do that, but it wouldn’t take long to search say 2018 or later and … There is the issue of how to get an overall ROB rating. … I would select a greater number of studies, including those that do and do not address the new concerns … I do not see a clear future research section Noted. … how many times a given intervention has been tested in an RCT.

449. Back (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/back.pdf
     January 01, 2011 - do they see this decision? … Slide  3: Why  do patients with advanced cancer continue  to choose  chemotherapy? … • Patients are willing to choose a palliative therapy for a level of benefit that is lower that what … • Me: got her email o my  god they’re going to do it • Clark: whenever Kitano  does something …  14: More  new approaches • Rethinking use of prognostic information and how to use it; looking

450. Disposition of Comments for Treatments for Seasonal Allergic Rhinitis (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/allergy-seasonal_disposition-comments.pdf
     July 17, 2013 - Did they refer to observational studies without an independent control group (case series and case … reports) or to non-randomized studies or some other study design? … I am also not sure if blinding was a necessary inclusion criterion, was just “addressed” (how?) … How did they determine that a given medication belonged to particular subgroup? … How the groups were defined?

451. Comparative Effectiveness Review Disposition of Comments Report (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/bundled-payments-quality-effects_disposition-comments.pdf
     August 24, 2012 - Medicaid, that other then have to figure out how to implement. … figure out how to allocate the dollars. … The authors do a good job of making this clear. No change in response to this comment. … the descriptions of how the system was designed and what it was intended to do should be expanded. … do to address what we don't know.

452. Radiotherapy Treatments for Head and Neck Cancer Update (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/head-neck-cancer-update_disposition.pdf
     December 09, 2014 - The CER update is meant to be a reflection of the state of published comparative evidence and how it … The primary rationale for this conclusion is that dosimetry studies do not provide a link to actual … In general, because dosimetry studies per se do not link to clinical outcomes in patients, we do not … In general, because dosimetry studies per se do not link to clinical outcomes in patients, we do not … In general, because dosimetry studies per se do not link to clinical outcomes in patients, we do not

453. Disposition of Comments for CER 153 Non-Muscle-Invasive Bladder Cancer (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/bladder-cancer-non-muscle-invasive_disposition-comments.pdf
     October 27, 2015 - this would include the EORTC risk calculator and CUETO risk calculators -- how do these classification … TEP Reviewer #1 Clarity and Usability how do the authors believe a blinded fluorescence trial … Studies often do not stratify patients according to these tumor characteristics. … How often will a subsequent work up in the setting of persistent hematuria reveal a urothelial malignancy … h) Triage patients presenting with micro- haematuria that do not need a full workup.

454. Research White Paper Patient- or Participant-Generated Registries Addendum Registries for Evaluating Patient Outcomes Third Edition (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/wysiwyg/patient-participant-generated-registries-guide-3rd-ed-addendum-white-paper.pdf
     February 01, 2018 - The PGRs responding to the survey also differ in how they are managed. … Also, researchers may not be sure how to deliver these insights back to participants in studies without … Participant Privacy and Confidentiality A fundamental question is how to allow access to the data available … for ensuring participants’ free choice of how, when, and who to allow access to their data. … Such efforts may be assisted through sharing of case studies that highlight successful uses of PGRs

455. Ced -Appendix-2 (xls file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/ced%20-appendix-2.xlsx
     May 29, 2025 - Guiding questions could have been more focused on: “how to prioritize research criteria to meet the goals … More important to focus on how and when CED should be used, before revising study requirements (concerns … For these reasons, we do not support the requirement that investigators provide information about algorithms … Provides recommendations for AHRQ about analyses it could do with CMS for evaluation of CED process … Guiding questions could have been more focused on: “how to prioritize research criteria to meet the goals

456. Disposition of Comments: Management of Suicidal Thoughts and Behaviors in Youth (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/suicidal-thoughts-youth-disposition-comments.pdf
     April 10, 2025 - The paper you describe primarily includes literature reviews and case studies and includes no trials … It is not feasible to do this in an abstract. … We also appreciate your ideas on how contributors to suicide are complex. … Needs to be clarified or refine the goals to what they were able to do. … could lead a person to suicide. We agree that this is important to do in clinical practice.

457. Technical Brief Disposition of Comments Report for Gene Expression Profiling for Predicting Outcomes in Stage II Colon Cancer (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/colon-cancer-gene-profiling_disposition-comments.pdf
     December 14, 2012 - The studies do not demonstrate an ability of the GEPs to classify patients into risk groups to help … give a sense of how well stage (and stage subgroups) separates patients into prognostic subsets. … Variants of genes seem to imply mutations which were also outside the scope and do not represent gene … However, as noted in the Brief, to demonstrate clinical utility data must be provided to show how … A detailed, net reclassification analysis (how patients in each risk group are impacted by use of

458. Musculoskeletal-Complaints-Tests-Children Executive (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/musculoskeletal-complaints-tests-children_executive.pdf
     March 01, 2012 - A complete history and physical examination is generally considered to be the best way to make a diagnosis … Key Questions In order to better understand how the ANA, RF, and CCP tests perform in the clinical setting … MSK pain and joint swelling) in children who do not have JIA and pSLE. … In children and adolescents aged 18 years or less with undiagnosed MSK pain and/or joint swelling, do … In children and adolescents aged 18 years or less with undiagnosed MSK pain and/or joint swelling, do

459. Liver-Cancer-Therapy Executive (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/liver-cancer-therapy_executive.pdf
     May 01, 2013 - Case reports will be considered only if they report on a rare adverse event. … studies, 35 case-series studies, and 3 case reports. … All included comparative studies were reviewed for KQ3, but case series and case reports were excluded … reports. … Case series do not use comparators.

460. Treating Infantile Hemangiomas in Children (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/infantile-hemangioma_consumer.pdf
     June 01, 2016 - do not grow normally. … � More research is needed to know how laser treatments compare with medicines to treat IHs. … � How long might it take for the IH to go away on its own? … � If a medicine might help my child, which one do you think may be best? … � How long might my child have to take the medicine?